Shop
eStoreRx™
Online Supplement Dispensary
Easy direct-to-patient ordering & fulfilment for Lifelong Wellness, eStoreRx™ is offered as part of the WholePractice membership or as a stand-alone program.
For over 40 years, Biotics Research Corporation has revolutionized the nutritional supplement industry by utilizing “The Best of Science and Nature”. Combining nature’s principles with scientific ingenuity, our products magnify the nutritional
This inclusive membership contains all of the the tools you need to grow your business, including WholeLifeRx™, Nimativ®, WholeLifeQ™, eStoreRx™ and Practice Success Programs.
Easy direct-to-patient ordering & fulfilment for Lifelong Wellness, eStoreRx™ is offered as part of the WholePractice membership or as a stand-alone program.
October 02 2024
Results of a single-blind placebo-controlled trial were recently published in BMC Pediatrics, indicating a beneficial effect of supplementation with v...
Results of a single-blind placebo-controlled trial were recently published in BMC Pediatrics, indicating a beneficial effect of supplementation with vitamin E enriched with tocotrienol (TRF) for children with obesity and non-alcoholic fatty liver disease (NAFLD). This follows a 24-week controlled trial among adults, in which delta-tocotrienol was shown to improve markers of steatosis and hepatocellular injury, including the fatty liver index (FLI), homeostasis model of insulin resistance (HOMA-IR), high sensitivity C-reactive protein (hs-CRP), malondialdehyde (MDA), alanine transaminase (ALT), and aspartate transaminase (AST).
In this trial, 32 Malaysian children (mean age of approximately 12 years old) received either placebo or a daily dose of 50 mg of vitamin E isomers (comprised 7.4 mg δ-tocotrienol, 2.02 mg β-tocotrienol, 22.3 mg γ-tocotrienol, 18.28 mg α-tocotrienol, and 17.1 mg α-tocopherol) for 6 months, with the trial’s primary outcome defined as the mean difference in hepatic steatosis as evaluated by the controlled attenuated parameter (CAP). Multiple secondary outcomes included fibrosis scores and biochemical assessments of inflammation, DNA damage, etc.
Among the 29 children who completed the trial, those who received TRF had significantly lower apolipoprotein-A1 (ApoA1) and aspartate aminotransferase (AST) levels after 6 months compared to baseline. Additionally, significant reductions were observed in pro-inflammatory cytokines (IL-6 and TNF-1) as well as DNA damage parameters (comet assay) after TRF supplementation. No differences were observed between groups for multiple secondary outcomes, including ALT, fasting blood glucose, α-2-M, GGT, haptoglobin, total bilirubin, and triglycerides. While a slight reduction in CAP was observed in the placebo group (perhaps due to behavioral changes), the decrease in the TRF group was not significant. No adverse effects were observed with TRF, suggesting that it may have a valuable role as a supportive and safe therapy for pediatric NAFLD, helping with oxidative damage and a healthy inflammatory response.
Submit this form and you'll receive our latest news and updates.
*These statements have not been evaluated by the Food and Drug Administration. This product has not intended to diagnose, treat, cure, or prevent any disease.
© 2023 Biotics Research Corporation - All Rights Reserved
Submit your comment